Close menu




September 27th, 2021 | 13:24 CEST

Valneva, Defence Therapeutics, CureVac - Second-tier vaccine makers offer high potential

  • Biotechnology
Photo credits: pixabay.com

The battle against the Coronavirus is still ongoing, although more and more people have been vaccinated with vector or mRNA vaccines. In Europe, an average of 60% of all people have received the vaccination. Herd immunity has not yet been achieved, in part because of vaccine skeptics who do not yet trust novel vaccines. New vaccines based on dead viruses promise to remedy the situation. This method has already been tried and tested in influenza vaccinations, for example. According to a study in Switzerland, about 70% of the unvaccinated would still be vaccinated if the method had already been tested. Herd immunity could thus be achieved, and everyday life could return to normal. So, which vaccine manufacturer that does not currently have an approved product could shake up the market?

time to read: 3 minutes | Author: Armin Schulz
ISIN: VALNEVA SE EO -_15 | FR0004056851 , DEFENCE THERAPEUTICS INC | CA24463V1013 , CUREVAC N.V. O.N. | NL0015436031

Table of contents:


    Valneva - Waiting for the results of the study

    The last month and a half has been a roller coaster ride for shareholders of French-Austrian Valneva. The stock shot up in mid-August, only to return to the starting point of the rally after the UK canceled the supply contract. As a result, sales of EUR 1.4 billion that were thought to be safe have been lost, even though the Phase 3 clinical trial results are not even available yet.

    These results are expected in October. If the results are positive, there should certainly be greater demand for the "classic" vaccine. Unlike many other Corona vaccine manufacturers, Valneva already has two vaccines on the market and other vaccines in the pipeline. Interestingly, they are working with Pfizer on the VLA15 vaccine. Pfizer has shown with BioNTech that it has backed the right horse before.

    CEO Thomas Lingelbach said, "We continue to receive daily messages from people around the world waiting for an inactivated vaccine, so we continue to believe that our differentiated vaccine candidate could contribute to the ongoing fight against the COVID-19 pandemic." The demand appears to be there. If the vaccine performs well, negotiations with the European Commission could become much easier. Above EUR 15.60, the sideways channel would be broken to the upside.

    Defence Therapeutics - Nasal Corona vaccine

    The Canadian biotech Company bases its drug development on the proprietary Accum technology. One component of the development pipeline is vaccines against infectious diseases, such as the Coronavirus. The Company is taking a different approach than many of its competitors. After researchers discovered that people infected with the Delta variant, in particular, had a viral load in the nasal cavity that was up to 1,260 times higher than that of the original Corona variant, the Company decided to take up the fight against the virus at the first site of infection.

    The AccuVAC-IN002 agent is administered intranasally. The CEO explained, "Defence's new AccuVAC-IN002 formulation enables us to elicit both IgA and IgG antibody responses at the systemic level and mucosal sites. This would have the effect of blocking transmission, thus not only stopping the initial infection but also ensuring nearly 100% blockage of viral release (shedding)." So far, the drug has only been tested on animals. It will be interesting to see how further studies turn out.

    In addition to developing the Corona vaccine, the Company also announced progress on its ventricular cell vaccine. Management plans to provide more detailed information soon. The stock is currently in an intact uptrend and is now consolidating. The chart remains bullish as long as the share price does not fall below CAD 6. At around CAD 243 million, the market capitalization is much more favorable than that of the competition.

    CureVac - Downsizing production capacities

    CureVac had been given a lot of advance praise. The Tuebingen-based Company was confident that it would be at the forefront of mRNA-based vaccine development. A history of delays and ultimately poor efficacy of the preparation made the Company a second-tier candidate. Initially, there was hope that they would present an optimized vaccine based on the new viral mutants. On August 16, the Company announced improved immune response and protective efficacy of its new vaccine variant.

    The share price promptly jumped again. However, a closer look at the news reveals that there is still a long way to go before approval is granted. The active ingredient was tested on monkeys. With the announcement on September 14, the Company once again disappointed its shareholders. The contracts with production partners Wacker and Celonic were terminated. Management justified the action with the adjustment of peak demand for vaccines. For the market, this simply meant that the Company itself no longer quite believed in its success.

    The share has since gone back into decline. However, the low of EUR 39.10 has not been taken out so far. The stock is in a sideways phase. The Company's development pipeline is full of prophylactic vaccines, cancer immunotherapies and protein-based therapies, all of which are primarily in preclinical development. So the road to a finished product is still long. For now, wait for positive news before jumping in.


    Even though all three companies have different approaches to the fight against Corona, they all have the same goal. Valneva is relying on a proven vaccination method and seems to be making the most progress at the moment. Defence Therapeutics is attacking the virus where it meets humans. Further progress should be watched closely. CureVac seems to be lagging at the moment. BioNTech and Moderna share the market for mRNA vaccines against Corona. Therefore, the prospects for CureVac are currently the worst. Nevertheless, for all three candidates, positive news can change everything.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST

    Evotec, Defence Therapeutics, Formycon - Biotech opportunity!

    • Biotechnology

    Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.

    Read